State of Alaska Department of Revenue Purchases 2,181 Shares of STAAR Surgical Company $STAA

State of Alaska Department of Revenue boosted its position in STAAR Surgical Company (NASDAQ:STAA) by 8.0% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 29,476 shares of the medical instruments supplier’s stock after purchasing an additional 2,181 shares during the period. State of Alaska Department of Revenue owned about 0.06% of STAAR Surgical worth $493,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC grew its position in shares of STAAR Surgical by 75.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 21,234 shares of the medical instruments supplier’s stock valued at $374,000 after acquiring an additional 9,125 shares during the period. Pinnacle Investment Management Ltd bought a new position in shares of STAAR Surgical during the 1st quarter valued at approximately $1,155,000. Strs Ohio bought a new position in shares of STAAR Surgical during the 1st quarter valued at approximately $190,000. Assenagon Asset Management S.A. grew its position in shares of STAAR Surgical by 213.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 164,088 shares of the medical instruments supplier’s stock valued at $2,753,000 after acquiring an additional 111,686 shares during the period. Finally, Caxton Associates LLP bought a new position in shares of STAAR Surgical during the 1st quarter valued at approximately $1,051,000. 96.70% of the stock is owned by institutional investors.

STAAR Surgical Trading Down 0.8%

STAA opened at $26.50 on Thursday. The company has a 50 day moving average of $26.83 and a 200 day moving average of $20.79. The company has a market cap of $1.31 billion, a PE ratio of -13.73 and a beta of 0.82. STAAR Surgical Company has a 12 month low of $13.50 and a 12 month high of $33.28.

Wall Street Analysts Forecast Growth

STAA has been the subject of a number of research reports. Stifel Nicolaus set a $28.00 target price on shares of STAAR Surgical and gave the company a “hold” rating in a research report on Thursday, August 7th. Mizuho increased their target price on shares of STAAR Surgical from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Piper Sandler raised shares of STAAR Surgical to a “hold” rating in a research report on Wednesday, June 18th. Canaccord Genuity Group increased their target price on shares of STAAR Surgical from $20.00 to $28.00 and gave the company a “hold” rating in a research report on Wednesday, August 6th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of STAAR Surgical in a research report on Wednesday. Ten investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $20.67.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.